# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate.
Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking t...
Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking t...
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses o...
2023 Financial ResultsRevenue for 2023 was $1.1 million, which was generated from the Company's research collaborations wit...